{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:11:05Z","timestamp":1790835065058,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["23OK1056"],"award-info":[{"award-number":["23OK1056"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","award":["NCT04745195"],"award-info":[{"award-number":["NCT04745195"]}],"id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent studies showed a high prevalence of monoclonal gammopathy (MG) in patients with thrombotic microangiopathy (TMA) aged over 50\u00a0years and suggested that complement dysregulation is pivotal for the disease to develop. Here, we studied this premise in seven patients with TMA and coexisting MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with TMA on kidney biopsy and\/or peripheral blood were recruited from the prospective COMPETE cohort (NCT04745195) and Limburg Renal Registry. Patients were screened for complement dysregulation, including genetics\/factor H autoantibodies (FHAA) and functional ex vivo testing on microvascular endothelial cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven (8%) out of 84 patients with TMA presented with a coexisting MG. MG clustered in patients aged over 50\u00a0years (n\/N\u00a0=\u00a06\/32, 19%). C4 and\/or C3 levels were low in three patients, while four patients presented with normal complement levels. None of the patients carried rare variants in complement genes. Massive ex vivo C5b9 formation on the endothelium was noted in one patient; purified IgG from this patient caused massive ex vivo C5b9 formation via the alternative pathway of complement activation, pointing to complement dysregulation in the fluid phase. Kidney biopsies from other nephropathies linked to MG rarely exhibited concurrent TMA (n\/N\u00a0=\u00a01\/27, 4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MG clustered in patients with TMA aged over 50 years. TMA and coexisting MG represents a heterogeneous disease spectrum, including a small subset of patients who may present with complement dysregulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfad306","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T18:51:35Z","timestamp":1703271095000},"source":"Crossref","is-referenced-by-count":8,"title":["The spectrum of thrombotic microangiopathy related to monoclonal gammopathy"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-2317","authenticated-orcid":false,"given":"Daan P C","family":"van Doorn","sequence":"first","affiliation":[{"name":"Department of Nephrology and Clinical Immunology, Maastricht University Medical Center , Maastricht , The Netherlands"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrurgia A","family":"Abdul-Hamid","sequence":"additional","affiliation":[{"name":"Department of Pathology, Maastricht University Medical Center , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A M","family":"Frenken","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Zuyderland Medical Center , Heerlen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Paassen","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Clinical Immunology, Maastricht University Medical Center , Maastricht , The Netherlands"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-2753","authenticated-orcid":false,"given":"Sjoerd A M E G","family":"Timmermans","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Clinical Immunology, Maastricht University Medical Center , Maastricht , The Netherlands"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Limburg Renal Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"2024011909264100500_bib1","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3390\/jcm10143034","article-title":"The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation","volume":"10","author":"Timmermans","year":"2021","journal-title":"JCM"},{"key":"2024011909264100500_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2024011909264100500_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"2024011909264100500_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2024011909264100500_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2024011909264100500_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1523-1755.2004.00835.x","article-title":"Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry","volume":"66","author":"van Paassen","year":"2004","journal-title":"Kidney Int"},{"key":"2024011909264100500_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"2024011909264100500_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","article-title":"Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes","volume":"6","author":"Timmermans","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024011909264100500_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"key":"2024011909264100500_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2019-1105","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins","volume":"58","author":"Jacobs","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2024011909264100500_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1515\/cclm-2019-1104","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis","volume":"58","author":"Turner","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2024011909264100500_bib12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2024011909264100500_bib13","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024011909264100500_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2024011909264100500_bib15","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J Immunol"},{"key":"2024011909264100500_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiol"},{"key":"2024011909264100500_bib17","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"JASN"},{"key":"2024011909264100500_bib18","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"2024011909264100500_bib19","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"2024011909264100500_bib20","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal gammopathy-associated thrombotic microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"American J Hematol"},{"key":"2024011909264100500_bib21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"2024011909264100500_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2024011909264100500_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"2024011909264100500_bib24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"J\u00f3zsi","year":"2008","journal-title":"Blood"},{"key":"2024011909264100500_bib25","doi-asserted-by":"crossref","first-page":"780107","DOI":"10.3389\/fimmu.2021.780107","article-title":"Thrombotic microangiopathy, an unusual form of monoclonal gammopathy of renal significance: report of 3 cases and literature review","volume":"12","author":"Filippone","year":"2021","journal-title":"Front Immunol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad306\/55152406\/sfad306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad306\/56247675\/sfad306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad306\/56247675\/sfad306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T04:27:27Z","timestamp":1705638447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfad306\/7513213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad306","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1]]},"article-number":"sfad306"}}